IDELVION Prevents Bleeds and Reduces Drug Consumption in Hemophilia B Patients
Results from the Phase III PROLONG9FP ongoing extension clinical development program evaluating the long-term efficacy and safety of IDELVION (coagulation factor IX [recombinant], albumin fusion protein) showed that extended prophylaxis treatment regimens effectively prevented bleeds while also reducing overall IDELVION consumption.
GSK’s Shingles Vaccine Effective in Adults 70-Plus Years Old
A randomized Phase III study (ZOE-70) of GlaxoSmithKline’s investigational shingles vaccine, Shingrix, showed 90 percent efficacy in adults aged 70 years and older that is maintained for at least four years.
Stem Cell Therapies: The Era of Regenerative Medicine?
Advancements in stem cell therapy may soon eliminate surgeries and cure disease, but first, the debate between two different schools of thought concerning how best to proceed needs to be resolved.
Recombinant Human Soluble Thrombomodulin May Improve Outcomes in Transplant-Associated Thrombotic Microangiopathy
Intravenous administration of recombinant soluble thrombomodulin (rTM) may improve recovery and survival compared to other treatments in patients with transplant-associated thrombotic microangiopathy (TA-TMA) after hematopoietic stem cell transplantation (HSCT), according to a retrospective analysis of 254 consecutive patients at a single Japanese institution.
Using Genomic Data to Personalize Cancer Treatment
Researchers are using genomics research to better understand how genetic variation contributes to human health and disease.
Recombinant Human Prothrombin Prevents Bleeding in Hemophilia A and B Mice
Both a plasma-derived human factor II (pdhFII) and an investigational recombinant human prothrombin (MEDI8111) dose-dependently decreased blood loss and bleeding time in hemophilia A mice, according to Swedish investigators at AstraZeneca’s CVMD IMED unit.
Real-Time Healthcare Monitoring
Mobile health technology is changing the way patient data is gathered and accessed, using real-time
analytics to improve outcomes and quality of care.
Study Provides Clues for Improving Effectiveness of Flu Vaccine
A new study found that seasonal flu vaccines work better if they stimulate an immune response to the flu surface protein neuraminidase.
Gene Therapy Results in Sustained Factor VIII Expression and Reduced Bleeding Episodes in Dogs with Severe Hemophilia A
Two young adult male dogs with severe hemophilia A treated with liver-targeted gene therapy experienced significant improvement in disease phenotype over follow-up periods of 31 months and 24 months, according to investigators at The Children’s Hospital of Philadelphia and the University of Pennsylvania.
Influenza Vaccine: A Universal Game Changer?
The efficacy of influenza (flu) vaccines has been greatly improved over the past several decades, but the flu virus still severely sickens hundreds of thousands of individuals each year. Is it possible that scientists have discovered a way to change that?
